LDS/Medical Tests/Kappa opioid receptor (OPRK1) Genotyping

Kappa opioid receptor (OPRK1) Genotyping

The kappa opioid receptor (OPRK1) is a member of the G-protein coupled receptor family that includes mu (OPRM1) and delta (OPRD1). It is able to bind multiple ligands. OPRK1 mediates ligand-directed signal trafficking, and thus has multiple downstream effects. OPRK1 activation decreases basal and drug-induced striatal levels of dopamine and has been associated with anti-nociceptive and prodepressive effects. OPRK1 association with antagonists has pro-nociceptive and antidepressant effects. The association between OPRK1 SNP variants and receptor activity has not been defined.

Importantly, antidepressant therapies have been associated with anxiety. OPRK1 antagonists, however, have anti-anxiety and antidepressant effects; thus, OPRK1 antagonists may be useful in cases of depression with anxiety.

Repeated cocaine exposure leads to persistent OPRK1 activation and may contribute to the persistent dysphoria associated with cocaine addiction and relapse.

The 36G>T variant in OPRK1 has been associated with vulnerability to opioid dependence.

  • Predicted response to smoking cessation therapy
  • Identifying candidates for OPRK1 antagonist therapy
  • Characterizing the nature of opioid dependence in chronic pain patients
Presence of the 36T variant allele has been associated with vulnerability to opioid dependence.

rs1051660 (36G>A) GG

Polymerase chain reaction followed by agarose gel electrophoresis for fragment analysis; real-time PCR with allele specific primer extension or ARMS; conventional sequencing; next-generation sequencing.

Whole blood (EDTA), Saliva, or Buccal swab. 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Dopamine, catecholamine, and serotonin levels, DRD2, Catechol-O-methyltransferase Genotyping (COMT), 5-HTT, and OPRM1 genotyping, Drug monitoring.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Pharmacogenetics. 2004 Dec;14(12):793-804. [PMID: 15608558]
  • Am J Med Genet B Neuropsychiatr Genet. 2007 Sep 5;144B(6): 771-5. [PMID: 17373729]
  • Guerrero M, Urbano M, Brown SJ, et al. Optimization and characterization of an opioid kappa receptor (OPRK1) antagonist. 2013 Apr 15 [Updated 2014 Sep 18]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010. Available from: http://www.ncbi.nlm.nih.gov/books/NBK179827/
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login